Ezetimibe licensed to reduce the risk of cardiovascular events

Ezetrol (ezetimibe) can now be prescribed to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome who are already receiving statin therapy or at the same time as initiating a statin.

For incremental cardiovascular event reduction, Ezetrol 10mg once daily may be administered with a statin. | SCIENCE PHOTO LIBRARY
For incremental cardiovascular event reduction, Ezetrol 10mg once daily may be administered with a statin. | SCIENCE PHOTO LIBRARY

The randomised, double-blind IMPROVE-IT trial enrolled patients who had been hospitalised for acute coronary syndrome within the preceding 10 days (n=18,144). Before hospitalisation, 34% of participants were already receiving statins.

Fewer cardiovascular events

Further information
View Ezetrol drug record
View Inegy drug record
Summary of Product Characteristics
MIMS Cardiology Clinic

The addition of ezetimibe to a starting dose of simvastatin 40mg provided incremental benefit in reducing the relative risk of the primary endpoint (a composite of cardiovascular death, non-fatal myocardial infarction, unstable angina requiring hospitalisation, coronary revascularisation and non-fatal stroke) by 6.4% compared with simvastatin alone.

At 7 years the primary endpoint occurred in 32.7% of patients in the ezetimibe/simvastatin group compared with 34.7% of patients in the simvastatin monotherapy group (HR 0.936; 95% CI 0.89—0.99, p=0.016).

LDL-cholesterol reduction

The median time-weighted average LDL cholesterol level over the course of the trial was 1.4mmol/L in the ezetimibe/simvastatin group and 1.8mmol/L in the simvastatin monotherapy group (p<0.001).

NICE recommendation

In February, NICE reaffirmed its guidance recommending ezetimibe monotherapy as an option for treating primary hypercholesterolaemia in adults unable to take statins. Ezetimibe can also be prescribed on the NHS in combination with initial statin therapy, as an option when statins fail to control serum total or LDL cholesterol levels, and when a change to an alternative statin is being considered.

Updated 8th March 2016

Ezetimibe/simvastatin fixed-dose combination (Inegy) also indicated to reduce cardiovascular risk 

Inegy (ezetimibe/simvastatin) is now also licensed to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome.

The recommended starting dose is one 10mg/40mg tablet once daily in the evening. This may be increased to 10mg/80mg only if the benefits are expected to outweigh the potential risks. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases